Sponsored post
It’s Time to “Face” the Facts About Rosacea – Educate Yourself and Break Up with Your Makeup for a Chance to Win a Trip to Los Angeles
While an estimated 16 million Americans suffer from rosacea, a common, chronic skin condition, many are unaware that it may go beyond the skin. Recent research suggests that, possibly due to its inflammatory nature, people with rosacea may be at an increased risk of a number of serious related health issues, including coronary artery disease, vascular disease, gastrointestinal disease and certain types of cancer. In an effort to support the millions of people suffering from rosacea, the National Rosacea Society, is partnering with Galderma Laboratories L.P., a financial sponsor, again to launch the third annual Break Up with Your Makeup campaign and contest.
Break Up with Your Makeup
Break Up with Your Makeup is a national campaign/contest that encourages those with rosacea to stop concealing and start treating. The goal is to educate the public about the signs and symptoms of rosacea and how to proactively manage the condition, while empowering sufferers to feel confident in their skin. As part of the contest, people with rosacea, or those who suspect they might have the condition, are encouraged to submit a no-makeup selfie and share how they would use the extra time if they could help alleviate their tough skin days and go makeup free. The winner of the contest will receive a spa get-away for two to sunny Los Angeles in 2016.
To enter the contest and help others who are struggling with similar skin challenges, individuals can log on to the Break Up with Your Makeup contest entry page starting on April 26, 2016 through May 20, 2016 to share their no-makeup selfie and personal skin story. In June, anyone over the age of 18 can view the photo gallery of contest finalists and vote for their favorites and be automatically entered into a sweepstakes for a chance to win one of three $500 gift card prizes. For more information about the campaign, please visit the Break Up with Your Makeup digital hub.
Education on Rosacea Still Needed
Although it affects nearly 16 million Americans, education on rosacea symptoms, triggers and treatment options is still needed. This recent research underscores the importance of recognizing the early warning signs of this chronic and often misdiagnosed skin condition. Galderma’s Break Up with Your Makeup initiative provides educational resources and encourages potential sufferers to seek accurate diagnosis and appropriate treatment.
Treatment Options are Available
Galderma offers a comprehensive portfolio of rosacea solutions that address a variety of frustrating symptoms for patients with the condition, including systemic Oracea® (doxycycline, USP) Capsules, 40 mg*, a convenient, once-daily oral treatment for the bumps and blemishes of rosacea; Soolantra® (ivermectin) Cream, 1%, a once-daily, antibiotic-free product indicated for the treatment of inflammatory lesions, or bumps and pimples, of rosacea; and Mirvaso® (brimonidine) Topical Gel, 0.33%** for persistent facial erythema (facial redness) associated with rosacea.
It’s time to “face” the facts about rosacea. Visit BreakUpWithMakeup.com to learn more about the condition, campaign and to enter the contest.
IMPORTANT SAFETY INFORMATION FOR ORACEA® CAPSULES, SOOLANTRA® CREAM AND MIRVASO® GEL
Important Safety Information
Indication: ORACEA® (doxycycline, USP) 40 mg* Capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. ORACEA Capsules do not lessen the facial redness caused by rosacea. Adverse Events: In controlled clinical studies, the most commonly reported adverse events (>2%) in patients treated with ORACEA Capsules were nasopharyngitis, sinusitis, diarrhea, hypertension and aspartate aminotransferase increase. Warnings/Precautions: ORACEA Capsules should not be used to treat or prevent infections. ORACEA Capsules should not be taken by patients who have a known hypersensitivity to doxycycline or other tetracyclines. ORACEA Capsules should not be taken during pregnancy, by nursing mothers, or during tooth development (up to the age of 8 years). Although photosensitivity was not observed in clinical trials, ORACEA Capsules patients should minimize or avoid exposure to natural or artificial sunlight. The efficacy of ORACEA Capsules treatment beyond 16 weeks and safety beyond 9 months have not been established.
*30 mg immediate release & 10 mg delayed release beads
Important Safety Information
Indication: SOOLANTRA® (ivermectin) Cream, 1% is indicated for the treatment of inflammatory lesions of rosacea. Adverse Events: In clinical trials with SOOLANTRA Cream, the most common adverse reactions (incidence < 1 %) included skin burning sensation and skin irritation. Warnings/Precautions: Not for oral, ophthalmic or intravaginal use.
Important Safety Information
Indication: MIRVASO® (brimonidine) topical gel, 0.33%** is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older. Adverse Events: In clinical trials, the most common adverse reactions (>1%) included erythema, flushing, skin burning sensation and contact dermatitis. Warnings/Precautions: MIRVASO Gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma, or Sjögren’s syndrome. Alpha-2 adrenergic agents can lower blood pressure. MIRVASO Gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease. Serious adverse reactions following accidental ingestion of MIRVASO Gel by children have been reported. Keep MIRVASO Gel out of reach of children. Not for oral, ophthalmic, or intravaginal use.
**Each gram of gel contains 5 mg of brimonidine tartrate, equivalent to 3.3 mg of brimonidine free base
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit All trademarks are the property of their owner.